- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01604291
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Afula, Israel, 18101
- Haemek Hospital; Gastroenterology
-
Ashkelon, Israel, 78278
- Barzilai MC; Gastroenterology
-
Beer Sheva, Israel, 84105
- Soroka Medical Center; Gastroenterology
-
Hadera, Israel, 38100
- Hillel Yaffe Hospital; Gastroenterology
-
Haifa, Israel, 31096
- Rambam Medical Center; Gastroenterology - Liver Unit
-
Haifa, Israel, 33394
- Bnei-Zion Medical Center; Gastroenterology
-
Haifa, Israel, 34362
- Carmel Hospital; Liver Unit
-
Holon, Israel, 58100
- Wolfson Hospital; Gastroenterology Unit
-
Jerusalem, Israel, 91031
- Shaare Zedek Hospital Liver Unit; Liver Unit
-
Jerusalem, Israel, 91120
- Hadassah Hospital; Liver Unit
-
Kfar Saba, Israel, 44281
- Meir Medical Center; Liver Unit
-
Nahariya, Israel, 22100
- Western Galilee Hospital - Nahariya
-
Nazareth, Israel
- Holy Family Medical Center; Liver Unit
-
Petach Tikva, Israel
- Hasharon Mc; Gastroenterology
-
Petah Tiqwa, Israel
- Beilinson-Rabin Liver Unit; Liver Unit
-
Ramat Gan, Israel, 5262100
- Sheba Medical Center; Tel Hashomer
-
Rehovot, Israel, 76100
- Kaplan Medical Center; Gastroenterology Unit
-
Safed, Israel, 13110
- Rebecca Sieff Medical Center; Liver Unit
-
Tel Aviv, Israel, 6423906
- Tel-Aviv Sourasky Medical Center; Liver Unit
-
Tiberias, Israel
- Poria Hospital; Gastroenterology
-
Zerifin, Israel, 6093000
- Assaf Harofeh; Gastroenterology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected or HCV-HIV co-infected)
- Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus ribavirin plus telaprevir/boceprevir)
- No contra-indications to Pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local Prescribing Information
- Quantitative serum HCV RNA by PCR test before initiation of treatment
Exclusion Criteria:
- Hepatitis A/B co-infection
- Evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- Pregnant or breast-feeding women
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
---|
Coorte
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Participants With Sustained Viral Response (SVR) at Week 24
Prazo: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
|
Week 24
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Comparison of SVR at Week 24
Prazo: Week 24
|
SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.
|
Week 24
|
Number of Participants With SVR at Week 24 According to the Demographic Characteristics
Prazo: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
Number of participants analysed signifies participants who were evaluated for outcome measure.
Data for this outcome measure was not summarized for each arm.
Hence, data is reported for all participants.
|
Week 24
|
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
Prazo: Week 4
|
RVR was defined as HCV-RNA <50 IU/mL by Week 4
|
Week 4
|
Percentage of Participants With Extended RVR
Prazo: Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Extended RVR was defined as HCV-RNA <50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 & 24 for participants treated with boceprevir. The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'. |
Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Percentage of Participants With Complete Early Virologic Response (cEVR)
Prazo: Week 12
|
Complete early virologic response (cEVR) was defined as HCV-RNA <50 IU/mL by Week 12
|
Week 12
|
Percentage of Participants With End of Treatment Response (EoT)
Prazo: Week 24
|
End-of-Treatment (EoT) response was defined as HCV-RNA <50 IU/mL by the end of treatment.
|
Week 24
|
Percentage of Participants With Virologic Relapse
Prazo: Week 72
|
Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA <50 IU/mL at EoT.
|
Week 72
|
Treatment Duration
Prazo: Week 48
|
The average amount of time a treatment was prescribed to participants.
|
Week 48
|
Time to First Dose Modification of Peginterferon Alfa-2a
Prazo: Week 48
|
Week 48
|
|
Time to First Dose Modification of Ribavirin
Prazo: Week 48
|
Week 48
|
|
Time to First Dose Modification of Telaprevir/Boceprevir
Prazo: Week 48
|
Week 48
|
|
Percentage of Participants With Adverse Events (AEs)
Prazo: Week 48
|
Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants. |
Week 48
|
Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia
Prazo: Week 48
|
Week 48
|
|
Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia
Prazo: Week 48
|
Week 48
|
|
Percentage of Participants Who Had SVR at Week 24 With Dose Modifications
Prazo: Week 24
|
Participants with dose modifications who had achieved SVR at Week 24 were reported.
Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.
|
Week 24
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças do Fígado
- Infecções por Flaviviridae
- Hepatite, Viral, Humana
- Infecções por Enterovírus
- Infecções por Picornaviridae
- Hepatite Crônica
- Hepatite
- Hepatite A
- Hepatite C
- Hepatite C Crônica
Outros números de identificação do estudo
- ML28268
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Hepatite C Crônica
-
Dokuz Eylul UniversityEge UniversityConcluídoMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CPeru
-
University College CorkDupont Applied BiosciencesRecrutamento
-
Trek Therapeutics, PBCConcluídoHepatite C crônica | Hepatite C Genótipo 1 | Hepatite C (VHC) | Infecção viral da hepatite CEstados Unidos, Nova Zelândia
-
Trek Therapeutics, PBCConcluídoHepatite C crônica | Hepatite C (VHC) | Hepatite C Genótipo 4 | Infecção viral da hepatite CEstados Unidos
-
Humanity and Health Research CentreBeijing 302 HospitalConcluídoInfecção Crônica por Hepatite CChina
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsRetiradoInfecção Crônica pelo Vírus da Hepatite CIsrael
-
Hadassah Medical OrganizationDesconhecidoInfecção Crônica pelo Vírus da Hepatite CIsrael
-
Beni-Suef UniversityConcluídoInfecção Crônica pelo Vírus da Hepatite CEgito
-
Meir Medical CenterConcluídoDesenvolvendo uma nova técnica de medição da relação C/D a partir de imagens digitais de disco óptico estéreo | Reprodutibilidade intraobservador das medidas de C/D | Variabilidade interobservador das medições C/D